Senses Disorder TRIZ Cases

Vitis vinifera leaf extract suppresses hearing threshold increases by inhibiting cytotoxicity and cell death in auditory cells.

Pharmacological fenofibrate treatment regulates PGC-1α levels to provide neuroprotection without the dopaminergic neuron loss caused by gene delivery methods.

Adjusting pH triggers PQQ salt precipitation, preventing thermal denaturation during room-temperature gelation.

Agonist stimulation of chemosensory receptors detects phenotypic expression to predict distilled spirit preferences.

Novel RPE65 inhibitors reduce toxic bisretinoid accumulation in the retina.

Quinazoline compounds overcome T790M mutation resistance by irreversibly inhibiting EGFR and HER-2 through covalent bonding.

Klotho fusion polypeptides combine Klotho and FGF23 via linkers to enhance serum half-life and binding affinity.

Systemic WT1 peptide treatment activates immune cells to prevent angiogenic diseases without invasive procedures or complex delivery infrastructure.

A multi-domain polypeptide combines convertase decay accelerating and cofactor domains to inhibit complement activation.

Pgk promoter-driven BCL2 expression prevents retinal ganglion cell degeneration and vision loss in glaucoma models.

An ophthalmic solution uses a specific copolymer to inhibit preservative adsorption on contact lenses.

Novel heterocyclic compounds inhibit insulin-like growth factor 1 receptor activity to address underlying pathogenic mechanisms in thyroid eye disease.

Artemisinin dimers inhibit cell proliferation via specific linkages to reduce chemotherapy side effects.

Upregulating genes encoding metabolic enzymes enhances intracellular glucose and NADPH levels, inhibiting cellular starvation in retinitis pigmentosa.

Combining hTert, hRb, and hE2F1 genes maintains biological relevance while enabling unlimited cell proliferation.

Targeted Pin1 inhibitors suppress oncogenic pathways by reducing protein expression, addressing side effects from broad immunosuppression.

Citric acid buffers gastric pH to neutralize proton pump inhibitors, maintaining bioavailability and reducing motor complications in Parkinson's disease.

Intravitreal injection of hyaluronic acid slows subretinal fluid accumulation to facilitate natural retinal reattachment.

Buffer salts, arginine, sucrose, and surfactants prevent aggregation of recombinant fusion proteins during freeze-thaw cycles.

Specific polymorphic forms prevent precipitation in ophthalmic solutions while maintaining bioavailability and reducing gastrointestinal toxicity.

Aqueous cyclodextrin suspensions deliver lipophilic drugs to the eye surface.

Mimotope vaccines target truncated amyloid-beta forms to reduce plaque burden without triggering autoimmune responses.

NMN and NR compositions improve Hsd3b6 enzymatic activity to treat meibomian gland dysfunction where retinoic acid efficacy remains limited.

Mutated anti-IGF-1R antibodies abolish FcRn binding, preventing systemic absorption while maintaining therapeutic efficacy in vascular eye diseases.

Sterol derivatives maintain auditory function by promoting axonal regrowth, avoiding side effects of neurotrophic factors like cancer risk.

Cyclodextrin forms an inclusion complex with astaxanthin to improve water solubility, addressing poor bioavailability in dry eye treatments.

Crystal structure of mutant calpain-5 protease core domain enables rational design of small molecule inhibitors.

Tankyrase-regulated naïve hiPSCs resolve differentiation variability and poor in vivo functionality by maintaining genomic stability.

Combining rhodopsin and melanopsin in a single cell overcomes slow response kinetics while restoring dim light sensitivity.

Histone deacetylase inhibitor carriers induce regulatory T cells to suppress interleukin-17, avoiding steroid-induced glaucoma.

Targeting both necrotic and apoptotic pathways with dual inhibitors reduces retinal ganglion cell death and promotes axon regeneration.

Sodium alginate eye inserts adjust dissolution time via multivalent salt exposure, reducing dosing frequency and blurred vision.

Optimized stabilizer ratios in atomized protein powders prevent degradation and aggregation during storage without refrigeration.

An anti-Plexin-A1 agonist antibody promotes dendritic cell contraction by binding to the C-terminal receptor region.

Substituted pyridine compounds activate the AMPK pathway by binding to the adiponectin receptor.

Aminopyrimidine compounds modulate FLT3, c-kit, and TrkB activity to address inadequate control of cell proliferation in cancer treatment.

Aptamers inhibit IL-6 mediated inflammation and proliferation, resolving limited efficacy of anti-TNF agents.

Mutant CoChR polypeptides restore vision by increasing light sensitivity and ion flux despite photoreceptor degeneration.

Salvia plebeia extract replaces immunogenic antibodies with small molecules to inhibit STAT3 phosphorylation and reduce autoimmune symptoms.

Codon-optimized nucleotide sequence boosts mitochondrial dynein-like GTPase expression to treat autosomal dominant optic atrophy.

Antisense oligonucleotides bypass viral cargo size limits by correcting aberrant CEP290 splicing through targeted exon skipping.

Biodegradable polymeric microparticles sustain drug release to overcome tear turnover barriers and reduce inflammation.

Humanized antibody binds amyloid beta proteins to inhibit aggregation and dissolve plaques while minimizing immunogenicity through local quality application.

ACT polypeptide promotes tissue regeneration via gap junction formation, reducing scar tissue and inflammation.

Administering complete Freund's adjuvant to mammals creates an eyelid disease model for screening therapeutic agents.

Monocyte lineage cell populations promote angiogenesis in ischemic myocardium.